Buccal Drug Delivery Systems Market Size, Share & Trends Analysis Report By Type (Buccal Tablets & Lozenges), By Application (Pain Management, Smoking Cessation, Angina Pectoris), By End-use, By Region, And Segment Forecast, 2024 - 2030

Buccal Drug Delivery Systems Market Size, Share & Trends Analysis Report By Type (Buccal Tablets & Lozenges), By Application (Pain Management, Smoking Cessation, Angina Pectoris), By End-use, By Region, And Segment Forecast, 2024 - 2030

Buccal Drug Delivery Systems Market Growth & Trends

The global buccal drug delivery systems market size is expected to reach USD 6.56 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 6.2% from 2024 to 2030. Buccal drug delivery systems have gained significant momentum since the last decade. Elimination of first-pass metabolism, quick absorption of the pH-sensitive drug, no interaction with stomach acid, quicker onset of action than any oral dose, minimal side effects, and reduced drug degradation are some of the factors fueling the market growth. Buccal drug delivery has gained large acceptance among geriatric patients and patients having difficulty swallowing.

Leading players like Generex, NovaDel, Biodiversity Sciences International, and Transcept Pharmaceuticals are constantly developing critical drugs like insulin, heparin, morphine, long-lasting pain analgesics, and some anti cardiac drugs into rapid mists, mucoadhesive discs, and lozenges. Commercialization of this research would eventually lead to being a major life savior as it would ensure the faster onset of action and eliminate drug degradation. Despite the increased R&D activity among market players, asteep decline was observed in the sales and revenue gainsdue to the outbreak of the Covid-19 pandemic. Except for covid medications, several other drug markets were majorly hit leading to the dip in the market for buccal drug delivery. However, it is expected to bounce back by 2022.

Buccal Drug Delivery Systems Market Report Highlights

• The buccal tablets and lozenges type segment accounted for the largest revenue share in 2023 due to its wider acceptance among patients
• The smoking cessation application segment held the largest share in 2023. Buccal drug delivery is often the most preferred and effective formulation for treating patients with smoking or nicotine addiction
• The hospital end-user segment captured the largest revenue share in 2023 owing to a large number of admissions of geriatric patients and abundant medication supplies
• North America held the largest revenue share in 2023 due to a large number of leading manufacturers and growing research in the region

Please note The report will be delivered in 2-3 business days upon order notification.